Bli medlem
Bli medlem

Du är här


AstraZeneca: AstraZeneca to discover and develop siRNA therapeutics for Cardiovascular, Renal, Metabolic and Respiratory di...

Collaboration with Silence Therapeutics aims to develop novel,
targeted treatments to address significant unmet need

AstraZeneca will collaborate with Silence Therapeutics to discover,
develop and commercialise small interfering RNA (siRNA) therapeutics
for the treatment of Cardiovascular, Renal, Metabolic and Respiratory

This multi-target collaboration will harness Silence's established
siRNA platform to identify and progress liver-based targets, as well
as developing new delivery approaches for targeting other tissues
such as the heart, lung and kidney. Targeted delivery to these other
tissues represents a new opportunity to treat Cardiovascular, Renal,
Metabolic and Respiratory diseases.

Mene Pangalos, EVP BioPharmaceuticals R&D, AstraZeneca said "This
collaboration with Silence adds an exciting new modality, siRNA, into
our drug discovery toolbox. Importantly we can apply this drug
modality across our key therapy areas in cardiovascular, renal and
metabolism and respiratory to target novel pathways not amenable to
more traditional drug discovery approaches."

Iain Ross, Executive Chairman at Silence said "We are delighted to
announce this collaboration with AstraZeneca as it is a further
validation of our proprietary siRNA platform. It not only provides us
with an opportunity to collaborate on specific liver expressed gene
targets but also to work with a leading company to achieve targeted
delivery of siRNA molecules to other tissues including heart, kidney
and lung."

Small interfering RNA (siRNA)

Small interfering RNA (siRNA) are double-stranded RNA molecules that
offer new opportunities for therapeutic intervention because they act
inside the cell to influence protein production. They do this by
targeting RNA to prevent the production of disease-causing


AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery, development
and commercialisation of prescription medicines, primarily for the
treatment of diseases in three therapy areas - Oncology,
Cardiovascular, Renal and Metabolism, and Respiratory. Based in
Cambridge, UK, AstraZeneca operates in over 100 countries and its
innovative medicines are used by millions of patients worldwide.
Please visit ( and follow
the Company on Twitter @AstraZeneca


For details on how to contact the Investor Relations Team, please
click here
( For
Media contacts, click here


1. Dana H Chalbatani GM, Mahmoodzadeh H et al. Int J Biomed Sci. 2017;
13(2): 48-57


Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.